Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial

We previously reported the results of a phase II/III, double‐blind, randomized controlled study in Chinese women (NCT00779766) showing a 94.2% (95% confidence interval: 62.7–99.9) HPV‐16/18 AS04‐adjuvanted vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or higher (CIN1+) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng‐cai, Hu, Shang‐Ying, Hong, Ying, Hu, Yue‐Mei, Zhang, Xun, Zhang, Yi‐Ju, Pan, Qin‐Jing, Zhang, Wen‐Hua, Zhao, Fang‐Hui, Zhang, Cheng‐Fu, Yang, Xiaoping, Yu, Jia‐Xi, Zhu, Jiahong, Zhu, Yejiang, Chen, Feng, Zhang, Qian, Wang, Hong, Wang, Changrong, Bi, Jun, Xue, Shiyin, Shen, Lingling, Zhang, Yan‐Shu, He, Yunkun, Tang, Haiwen, Karkada, Naveen, Suryakiran, Pemmaraju, Bi, Dan, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269697/
https://www.ncbi.nlm.nih.gov/pubmed/27998015
http://dx.doi.org/10.1002/cam4.869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269697/
https://www.ncbi.nlm.nih.gov/pubmed/27998015
http://dx.doi.org/10.1002/cam4.869

Ejemplares similares